Citations

Showing 10 of 108094 citations.

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials
Aycardi, Ernesto, Bigal, Marcelo E. , Loupe, Pippa S., McDonald, Mirna, Dodick, David W. , Halker Singh, Rashmi B, Dodick, David W , Singh, Rashmi B. Halker

Mayo Clinic

Cephalalgia | May 3, 2018 | Volume: 39 | Issue: 1 | Pages: 52-60

10.1177/0333102418772585 | PMID 29722276 Get It

Background In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and chronic migraine (CM). Objective Post-hoc analyses evaluated population-wise 50%, 75% and 100% responder rates, and the extent to which individual responders sustained a 50%, 75% and 100% reduction in migraine days, moderate-to-severe (M/S) headache days and days of acute medication use during all three treatment months of the fremanezumab phase 2 studies. Design/methods HFEM patients received either placebo or three once-monthly injections of 225 mg or 675 mg. CM patients received either placebo or three once-monthly injections of 900 mg, or an initial loading dose of 675 mg and subsequent injections of 225 mg. Patients reported headache-related data daily using an electronic diary. Results In the HFEM study, the percent of patients on fremanezumab doses 225 mg and 675 mg were greater compared to the percent of placebo patients with sustained 50% reduction in migraine days (39% and 35% vs. 10% for placebo, both p < 0.0001), M/S headache days (36% and 38% vs. 16% placebo, p = 0.0017 and p = 0.0007 respectively), and acute medication use days (36% and 27% vs. 8% placebo, p < 0.0001 and p = 0.0003). Likewise, although there were fewer patients with sustained 75% reduction, there were increases in the percent of patients on fremanezumab 225 mg and 675 mg in the HFEM study relative to placebo patients in migraine days (19% and 11% vs. 3% placebo, p = 0.0002 and p = 0.0176), M/S headache days (19% and 15% vs. 2% placebo, p = 0.0001 and p = 0.0011) and days of acute medication use (16% and 8% vs. 2% placebo, p = 0.0005 and p = 0.0377). In the CM study, there were increases in the percent of patients on fremanezumab 675/225 mg and 900 mg with 50% sustained reduction in M/S headache days (32% and 40% vs. 15% placebo, p = 0.0058 and p = 0.0002) and days of acute medication use (26% and 22% vs. 11% placebo, p = 0.0098 and p = 0.0492). There were also increases in the percent of patients on fremanezumab 675/225 mg and 900 mg compared to patients on placebo with 75% sustained reduction in M/S headache days (10% and 13% vs. 3%, p = 0.0665 and p = 0.0203). Few patients had 100% sustained reductions in these parameters in either study. Conclusions Post-hoc results must be interpreted with caution; nonetheless, a statistically significant percentage of patients who initially responded to fremanezumab within 1 month sustained this response over the subsequent 2 months. Sustained reduction in individual patients may provide a novel patient-centric, clinically meaningful endpoint for future trials assessing the effectiveness of preventive migraine treatments. Trials are registered as http://clinical trials.gov as NCT02025556 and NCT02021773.
Pulmonary Mycobacterial Spindle Cell Pseudotumor: A Report of 3 Cases Including a Practical Approach to Histopathologic Recognition of This Unusual Entity
Boylan, Katherine , Larsen, Brandon T. , Young, Brittany , Downs‐Kelly, Erinn, Panchabhai, Tanmay S. , Collum, Earle S., Jensen, Leif , Emerson, Lyska L. , Jensen, Leif

Mayo Clinic

International Journal of Surgical Pathology | May 3, 2018 | Volume: 26 | Issue: 7 | Pages: 629-634

10.1177/1066896918770010 | PMID 29720005 Get It

Mycobacterial spindle cell pseudotumor (MSP) is a rare benign spindle cell lesion containing acid-fact mycobacteria. These lesions are most commonly identified in the lymph nodes, skin, spleen, or bone marrow of immunocompromised patients and only rarely involve the lungs. We report 3 cases of pulmonary MSP, which include 2 patients who are known to be HIV-positive. The histopathological diagnosis of MSP in the lung lends itself to many challenges due to its rare incidence and its spindled tumor-like appearance. The differential diagnosis is broad and includes both benign and malignant entities. We highlight the importance of the clinical context in which these lesions typically present and the morphologic spectrum of features seen, and we offer a practical approach to the workup of pulmonary mycobacterial pseudotumor. Appropriate recognition of this entity should lead to an accurate diagnosis of a treatable benign condition despite the clinical presentation often favoring malignancy.
Gastrodoudenal Embolization: Indications, Technical Pearls, and Outcomes
Kuyumcu, Gokhan, Latich, Igor , Hardman, Rulon L., Fine, G , Öklü, Rahmi , Quencer, Keith , Quencer, Keith B , Oklu, Rahmi

Mayo Clinic

Journal of Clinical Medicine | May 3, 2018 | Volume: 7 | Issue: 5 | Pages: 101

10.3390/jcm7050101 | PMID 29724061 Get It

The gastroduodenal artery (GDA) is frequently embolized in cases of upper GI bleed that has failed endoscopic therapy. Additionally, it may be done for GDA pseudoaneurysms or as an adjunctive procedure prior to Yttrim-90 (Y90) treatment of hepatic tumors. This clinical review will summarize anatomy and embryology of the GDA, indications, outcomes and complications of GDA embolization.
Bleeding after Percutaneous Transhepatic Biliary Drainage: Incidence, Causes and Treatments
Quencer, Keith , Tadros, Anthony , Marashi, Keyan B, Cizman, Ziga , O’Hara, Ryan , Öklü, Rahmi , Quencer, Keith B , Oklu, Rahmi , Reiner, Eric J.

Mayo Clinic

Journal of Clinical Medicine | May 3, 2018 | Volume: 7 | Issue: 5 | Pages: 94

10.3390/jcm7050094 | PMID 29723964 Get It

Of all procedures in interventional radiology, percutaneous transhepatic biliary drainage (PTBD) is amongst the most technically challenging. Successful placement requires a high level of assorted skills. While this procedure can be life-saving, it can also lead to significant iatrogenic harm, often manifesting as bleeding. Readers of this article will come to understand the pathophysiology and anatomy underlying post-PTBD bleeding, its incidence, its varied clinical manifestations and its initial management. Additionally, a structured approach to its treatment emphasizing endovascular and percutaneous methods is given.
Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension
Helgeson, Scott A. , Imam, J. Saadi , Moss, John E. , Hodge, David O. , Burger, Charles D. , Helgeson, Scott A , Burger, Charles

Mayo Clinic

Diseases | May 3, 2018 | Volume: 6 | Issue: 2 | Pages: 33

10.3390/diseases6020033 | PMID 29723983 Get It

Pulmonary arterial hypertension (PAH) is a progressive disease that requires validated biomarkers of disease severity. While PAH is defined hemodynamically by right heart catheterization (RHC), brain natriuretic peptide (BNP) is recommended by guidelines to assess disease status. Retrospectively collected data in 138 group 1 PAH patients were examined for the correlation of BNP levels to simultaneously obtained right heart catheterization (RHC). Patients were mostly Caucasian women, with functional class III symptoms, mean BNP of 406 ± 443 pg/mL, and an average right atrial pressure (RAP) of 9.9 ± 5.7 mm Hg and mean pulmonary artery pressure (mPAP) of 47.3 ± 14.7 mm Hg. Significant correlation was demonstrated between BNP and RAP (p = 0.021) and mPAP (p = 0.003). Additional correlation was seen with right heart size on echocardiography: right atrial (RAE; p = 0.04) and right ventricular enlargement (p = 0.03). An increased BNP level was an independent predictor of mortality (p < 0.0001), along with RAP (p = 0.039) and RAE (p = 0.018). Simultaneous collection of BNP at the time of RHC confirmed the correlation of BNP with right heart hemodynamics. The current results reinforce the use of BNP level as a continuous variable to assess disease severity in group 1 PAH.
Eros and Illness: Morris
Wilson, Peter R, Wilson, Peter R

Mayo Clinic

Pain Medicine | May 3, 2018 | Volume: 19 | Issue: 7 | Pages: 1494-1496

10.1093/pm/pny089 Get It

Association of Total Fluid Intake and Output with Duration of Hospital Stay in Patients with Acute Pancreatitis
Koop, Andree , Jackson, Jillian K., Henry, April, Horsley‐Silva, Jennifer L. , Pannala, Rahul , Heckman, Michael G. , Diehl, Nancy N. , Palmer, William C. , Koop, Andree H , Stancampiano, Fernando F , Jackson, Jillian, Horsley-Silva, Jennifer, Heckman, Michael G , Diehl, Nancy N , Palmer, William C , Stancampiano, Fernando F.

Mayo Clinic

Gastroenterology Research and Practice | May 2, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-8

10.1155/2018/7614381 | PMID 29853865 Get It

Background/Aims. The aim of this study was to evaluate the association of fluid balance with outcomes in patients hospitalized with acute pancreatitis (AP).Methods. This was a retrospective study of patients hospitalized between May 2008 and June 2016 with AP and a clinical order for strict recording of intake and output. Data collected included various types of fluid intake and output at 24 and 48 hours after admission. The primary outcome was length of stay (LOS). Analysis was performed using single-variable and multivariable negative binomial regression models.Results. Of 1256 patients hospitalized for AP during the study period, only 71 patients (5.6%) had a clinical order for strict recording of intake and output. Increased urine output was associated with a decreased LOS at 24 and 48 hours in univariable analysis. An increasingly positive fluid balance (total intake minus urine output) at 24 hours was associated with a longer LOS in multivariable analysis.Conclusions. Few patients hospitalized for AP had a documented order for strict monitoring of fluid intake and output, despite the importance of monitoring fluid balance in these patients. Our study suggests an association between urine output and fluid balance with LOS in AP.
Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men
Loprinzi, Charles L. , Deville, Curtiland , Deville, Curtiland , Smith, Thomas J.

Mayo Clinic

New England Journal of Medicine | May 2, 2018 | Volume: 378 | Issue: 18 | Pages: 1745-1746

10.1056/nejmc1801992 | PMID 29719180 Get It

Differences in lumbar motor neuron pruning in an animal model of early onset spasticity
Brandenburg, Joline E. , Gransee, Heather M. , Fogarty, Matthew J. , Gransee, Heather M , Sieck, Gary C. , Fogarty, Matthew J

Mayo Clinic

Journal of Neurophysiology | May 2, 2018 | Volume: 120 | Issue: 2 | Pages: 601-609

10.1152/jn.00186.2018 | PMID 29718808 Get It

Motor neuron (MN) development in early onset spasticity is poorly understood. For example, spastic cerebral palsy (sCP), the most common motor disability of childhood, is poorly predicted by brain imaging, yet research remains focused on the brain. By contrast, MNs, via the motor unit and neurotransmitter signaling, are the target of most therapeutic spasticity treatments and are the final common output of motor control. MN development in sCP is a critical knowledge gap, because the late embryonic and postnatal periods are not only when the supposed brain injury occurs but also are critical times for spinal cord neuromotor development. Using an animal model of early onset spasticity [ spa mouse (B6.Cg- Glrbspa/J) with a glycine (Gly) receptor mutation], we hypothesized that removal of effective glycinergic neurotransmitter inputs to MNs during development will influence MN pruning (including primary dendrites) and MN size. Spa (Glrb−/−) and wild-type (Glrb+/+) mice, ages 4–9 wk, underwent unilateral retrograde labeling of the tibialis anterior muscle MNs via peroneal nerve dip in tetramethylrhodamine. After 3 days, mice were euthanized and perfused with 4% paraformaldehyde, and the spinal cord was excised and processed for confocal imaging. Spa mice had ~61% fewer lumbar tibialis anterior MNs ( P < 0.01), disproportionately affecting larger MNs. Additionally, a ~23% reduction in tibialis anterior MN somal surface area ( P < 0.01) and a 12% increase in primary dendrites ( P = 0.046) were observed. Thus MN pruning and MN somal surface area are abnormal in early onset spasticity. Fewer and smaller MNs may contribute to the spastic phenotype.NEW & NOTEWORTHY Motor neuron (MN) development in early onset spasticity is poorly understood. In an animal model of early onset spasticity, spa mice, we found ~61% fewer lumbar tibialis anterior MNs compared with controls. This MN loss disproportionately affected larger MNs. Thus number and heterogeneity of the MN pool are decreased in spa mice, likely contributing to the spastic phenotype.
Feasibility and agreement of stiffness measurements using gradient-echo and spin-echo MR elastography sequences in unselected patients undergoing liver MRI
Cunha, Guilherme Moura , Glaser, Kevin J. , Bergman, Anke, Luz, Rodrigo, Figueiredo, Eduardo H de, Lopes, Flávia Paiva Proença Lobo

Mayo Clinic

The British Journal of Radiology | May 2, 2018 | Volume: No volume available | Issue: No issue available | Pages: 20180126

10.1259/bjr.20180126 | PMID 29718694 Get It